Cantor Fitzgerald Reaffirms Buy Rating for TherapeuticsMD (TXMD)
TherapeuticsMD (NASDAQ:TXMD)‘s stock had its “buy” rating reiterated by stock analysts at Cantor Fitzgerald in a research report issued on Wednesday. They presently have a $31.00 price target on the stock. Cantor Fitzgerald’s price objective suggests a potential upside of 395.21% from the company’s previous close.
A number of other equities analysts have also weighed in on the stock. BidaskClub upgraded shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a report on Friday, September 8th. Morgan Stanley started coverage on shares of TherapeuticsMD in a report on Friday, September 8th. They issued an “equal weight” rating and a $6.00 price objective for the company. Deutsche Bank restated a “buy” rating and issued a $10.00 price objective on shares of TherapeuticsMD in a report on Wednesday, September 13th. Jefferies Group restated a “buy” rating and issued a $15.00 price objective on shares of TherapeuticsMD in a report on Friday, September 8th. Finally, Cowen restated an “outperform” rating and issued a $16.00 price objective (up from $13.00) on shares of TherapeuticsMD in a report on Monday, November 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $14.50.
Shares of TherapeuticsMD (NASDAQ TXMD) traded up $0.19 during midday trading on Wednesday, reaching $6.26. 2,882,514 shares of the company were exchanged, compared to its average volume of 2,892,935. TherapeuticsMD has a 52 week low of $3.50 and a 52 week high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Monday, November 6th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The company had revenue of $4.42 million during the quarter, compared to analyst estimates of $5.36 million. During the same period in the previous year, the business earned ($0.13) EPS. The firm’s revenue for the quarter was down 19.7% on a year-over-year basis. analysts anticipate that TherapeuticsMD will post -0.37 earnings per share for the current year.
A number of large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its position in TherapeuticsMD by 13.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 25,877,864 shares of the company’s stock worth $136,894,000 after purchasing an additional 2,985,846 shares during the period. JPMorgan Chase & Co. grew its position in TherapeuticsMD by 40.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,027,855 shares of the company’s stock worth $112,783,000 after purchasing an additional 6,340,346 shares during the period. Vanguard Group Inc. grew its position in TherapeuticsMD by 4.4% in the 2nd quarter. Vanguard Group Inc. now owns 10,231,081 shares of the company’s stock worth $53,918,000 after purchasing an additional 429,211 shares during the period. State Street Corp grew its position in TherapeuticsMD by 14.9% in the 2nd quarter. State Street Corp now owns 4,486,585 shares of the company’s stock worth $23,647,000 after purchasing an additional 583,094 shares during the period. Finally, Voya Investment Management LLC grew its position in TherapeuticsMD by 33.4% in the 2nd quarter. Voya Investment Management LLC now owns 2,959,107 shares of the company’s stock worth $15,595,000 after purchasing an additional 741,588 shares during the period. 73.72% of the stock is owned by institutional investors and hedge funds.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.